96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 29750 | Michail Ignatiadis | Breast | EORTC | 2129 - TREAT ctDNA | Trial open for recruitment | Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
| 28802 | Philippe Aftimos | Breast | Ayala Pharmaceuticals, Inc. | AL-TNBC-01 - TENACITY | Trial closed | A Phase 2, Multicenter, Open-label, Single arm Study of AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer | philippe.aftimos@hubruxelles.be | 2 | 2 | ||
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22814 | Non metastatic, operable HER2+ carcinoma of the breast | Martine Piccart | Breast | Roche | APHINITY | Trial closed for recruitment | A randomised multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. | martine.piccart@hubruxelles.be | |||
| 22704 | Stage II or stage III, early invasive breast cancer. ER+/HER2- | Michail Ignatiadis | Breast | EORTC | APPALACHES | Trial closed for recruitment | A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES) (PILOT039) | michail.ignatiadis@hubruxelles.be | 2 | 2 | |
| 22661 | 3rd line metastatic | Philippe Aftimos | Breast | Immunomedics | Ascent | Trial closed | An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 29591 | Evandro De Azambuja | Breast | Gilead Science | ASCENT-04 | Trial open for recruitment | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 | 3 | 3 | |||
| 22615 | after one line, biopsy | Philippe Aftimos | Breast | BIG | AURORA | Trial open for recruitment | BIG 14-01 AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 22693 | HER+. Advanced or metastatic with PIK3CA mutation | Philippe Aftimos | Breast | Menarini | B PRECISE 01 | Trial closed | Open-label, multicentre, phase Ib dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab +/- fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22935 | Subject was previously enrolled in a selected company-sponsored feeder trial, and has received at least 1 dose of radium-223 dichloride or placebo in the feeder trial. | Géraldine Gebhart | Multiple | Bayer | BAY 88-8223 / 16996 | Trial closed for recruitment | A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride | geraldine.gebhart@hubruxelles.be | 4 | 4 | |
| 22619 | *HER negative hormone receptor positive breast cancer * received at least one line of hormonal therapy in the metastatic setting *eligible for exemestane and everolimus * experienced no more than 2 skeletal related event (SRE) |
Géraldine Gebhart | Breast | Bayer | BAY 88-8223 / 17096 | Trial closed for recruitment | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases | geraldine.gebhart@hubruxelles.be | 2 | 2 | |
| 22827 | TNBC | Daphné t'Kint de Roodenbeke | Breast | UZ-Brussel | BSMO 2014 01 | Trial closed | A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negative breast cancer | daphne.tkint@hubruxelles.be | 2 | 2 | |
| 22758 | ECOG 0 or 1 | Ahmad Hussein Awada | Multiple | BMS - Bristol Myers Squibb int. | CA209358 | Trial closed | Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors | ahmad.awada@hubruxelles.be | 1/2 | 1 |